Actavis Said Near Deal to Buy Allergan MICHAEL J. DE LA MERCED Under the proposed terms of the transaction, Actavis would pay more than $210 a share, people briefed on the matter said. An agreement could thwart a monthslong hostile bid for Allergan by Valeant Pharmaceuticals International. November 16, 2014 at 12:00AM http://nyti.ms/14vy6T3 The New York Times Business Day Drugs (Pharmaceuticals), Mergers, Acquisitions and Divestitures

By MICHAEL J. DE LA MERCED via NYT / Eethg. Corps. Inc. / Terrence Herschel G. Business Day http://nyti.ms/14vy6T3 Actavis Said Near Deal to Buy Allergan November 16, 2014 at 12:00AM The New York Times